A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma (NCT01677390)
This is a phase I, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 (vorsetuzumab mafodotin) in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
This trial is sponsored by Seattle Genetics. 
- Condition: Renal Cell Carcinoma
- Phase: I
- Enrollment: 4
- Start: August 2012
- Completion: December 2013
- Last verified: January 2014
Last Editorial review: July 14, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.